Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Antabio

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310

              Contact the Supplier

              Lead Product(s): ANT3310,Meropenem

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 06, 2020

              Details:

              QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.

              MedinCell

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin

              Contact the Supplier

              Lead Product(s): Ivermectin

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 06, 2020

              Details:

              Study reveal that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ?5000-fold reduction in 48h in cell culture.

              PharmaCompass__DigitalAd